explore -WSS

explore

author：knowledge 2025-08-12 09:13:04 - browse：4816

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

hotspot

WSS

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Liz Cheney makes 1st public comment since Trump's election interference indictments

The UK government moves asylum

Eye stem cell transplant could help restore vision in injured people

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

hotspot

explore

hotspot

Peter Hotez and the public health issue of online harassment

New details revealed about Purdue's marketing of OxyContin

Apple is now the first public company to be valued at $3 trillion

Baltimore teen accused of firing into crowd during block party mass shooting

Medical records are filled with copy

New details revealed about Purdue's marketing of OxyContin

As demand for Covid shots wanes, Moderna seeks its next success

Baltimore teen accused of firing into crowd during block party mass shooting

Continuity nursing helped my family in our darkest PICU moments

Democratic lawmaker calls for 'well

Wikipedia

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

New details revealed about Purdue's marketing of OxyContin

An interview with Robert F. Kennedy Jr. on vaccines

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Hilary expected to bring catastrophic, life

Evacuations in place as 3 wildfires burn in eastern Washington state

focus

hotspot

leisure time

entertainment